MetaCap

ADARx Pharmaceuticals Inc. (ADRX)

NASDAQ: ADRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

12.79-1.37 (-9.68%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ADRX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$6.75
52-week range
12.50 – 23.21
Day range
12.66 – 14.86
Volume / Avg
708.82K / 650.63K
Beta
—

52-week range

$12.50$23.21

ADRX stock today

ADARx Pharmaceuticals (ADRX) closed at $12.79 on Nov 20, down 9.68% (-$1.37), versus the S&P 500's 3.70% decline. Shares are 44.9% below their 52-week high of $23.21, set on Sep 25, 2026 and 2.3% above the 52-week low of $12.50, near the bottom of the past year's range. ADARx Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$6.75), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About ADARx Pharmaceuticals

Company profile

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Li Zhen Ph.D.
Headquarters
San Diego, CA
Employees
100
IPO year
2026
Website
adarx.com

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$34.25+167.79%

  • Strong buy 2
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $32.00High $38.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-1.74 vs $-0.40
Surprise
-335.00%

ADRX news

All ADRX news

ADARx Pharmaceuticals peers

Health Care sector
ADRX peer companies
CompanyPrice% ChgMarket capCompare
SRPTSarepta Therapeutics Inc.13.33-5.93%$1.43Bvs ADRX
KLRAKailera Therapeutics Inc.11.02-4.84%$1.43Bvs ADRX
DMRADamora Therapeutics Inc.23.22-4.44%$1.44Bvs ADRX
NRIXNurix Therapeutics Inc.12.85-5.55%$1.40Bvs ADRX
TYRATyra Biosciences Inc.20.12+1.98%$1.39Bvs ADRX
ANABAnaptysBio Inc.46.63-1.62%$1.39Bvs ADRX
RAPPRapport Therapeutics Inc.23.16-1.82%$1.37Bvs ADRX
QUREuniQure N.V.19.35-4.35%$1.36Bvs ADRX

Indexes, lists and sector

ADARx Pharmaceuticals stock FAQ

What is ADARx Pharmaceuticals's stock price today?

ADRX last traded at $12.79 as of Nov 20, 4:00 PM EST, down 9.68% on the day. Prices are delayed at least 15 minutes.

Who is ADARx Pharmaceuticals's CEO?

Dr. Li Zhen Ph.D. is the chief executive officer of ADARx Pharmaceuticals Inc., which has about 100 employees.

What is the ADRX 52-week high?

The 52-week high for ADRX is $23.21 and the 52-week low is $12.50. The stock is currently 44.9% below its high.

Compare ADRX